(RTTNews) - Dyne Therapeutics (DYN) announced that the Ministry of Health, Labour and Welfare in Japan has granted Orphan Drug designation for DYNE-251 in individuals with Duchenne muscular dystrophy who have mutations in the DMD gene that are amenable to exon 51 skipping. DYNE-251 is being evaluated in the Phase 1/2 DELIVER clinical trial.
Doug Kerr, chief medical officer of Dyne, said: "With orphan drug designation now granted in Japan, complementing existing designations in the U.S. and Europe, DYNE-251 continues to advance as a promising next-generation exon 51 skipping therapy."
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
